www.fdanews.com/articles/74336-novartis-to-acquire-bristol-myers-otc-portfolio
NOVARTIS TO ACQUIRE BRISTOL-MYERS OTC PORTFOLIO
July 15, 2005
Swiss drugmaker Novartis (NOVN.VX: Quote, Profile, Research) said on Thursday it will pay $660 million for the rights to produce and market Bristol-Myers Squibb Co.'s (BMY.N: Quote, Profile, Research) North American over-the-counter products, including the painkiller Excedrin. Other brands included in the deal are Keri, No-Doz, and Comtrex, Novartis said in a statement.